Mamoun Younes1, Keith Brown2, Gregory Y Lauwers3, Gulchin Ergun4, Frank Meriano4, A Carl Schmulen4, Alberto Barroso4, Atilla Ertan5. 1. Department of Pathology and Laboratory Medicine, University of Texas Health Science Center at Houston, McGovern Medical School, and Memorial Hermann Hospital-TMC, Houston, TX, USA. 2. Department of Pathology, Baylor College of Medicine, Houston, TX, USA. 3. Department of Anatomic Pathology, H. Lee Moffitt Cancer Center, Tampa, FL, USA. 4. Section of Gastroenterology, Department of Medicine, Houston Methodist Hospital, Houston, TX, USA. 5. Section of Gastroenterology, Hepatology and Nutrition, Department of Medicine, University of Texas Health Science Center at Houston, McGovern Medical School, and Memorial Hermann Hospital-TMC, Houston, TX, USA.
Abstract
AIMS: The purpose of this study was to determine prospectively whether p53 protein accumulation in biopsies of Barrett's metaplasia (BM) is a predictor of malignant progression, without relying on dysplasia grading. METHODS AND RESULTS: Sections of formalin-fixed paraffin-embedded tissue from the initial biopsies of 275 patients with BM, who had no high-grade dysplasia (HGD) or oesophageal adenocarcinoma (EAC), were stained for p53 by immunohistochemistry. The mean follow-up was 41 months. p53-positive biopsies were divided into four groups: scattered positive cells, multifocal scattered positive cells, aggregates of positive cells, and multifocal aggregates of positive cells. Kaplan-Meier analysis with the log-rank test was used to determine the rate of progression to HGD/EAC. Of the 275 patients, 227 had initial biopsies that were completely negative for p53, and, of these, one (0.4%) progressed to HGD/EAC; none of 24 (0%) patients with scattered positive cells and none of four (0%) of patients with multifocal scattered positive cells progressed. In contrast, five of 16 (31.25%) patients with aggregates of positive cells and three of four (75%) of those with multifocal aggregates of positive cells progressed to HGD/EAC. Kaplan-Meier analysis with log-rank statistics showed the difference in progression rate between the five groups to be highly significant (P < 0.0001). CONCLUSIONS: We conclude that p53 protein accumulation, detected by immunohistochemistry in aggregates of cells, is a significant predictor of malignant progression in patients with BM.
AIMS: The purpose of this study was to determine prospectively whether n class="Chemical">pan class="Gene">p53n> protein accumulation in biopsies of pan>n class="Disease">Barrett's metaplasia (BM) is a predictor of malignant progression, without relying on dysplasia grading. METHODS AND RESULTS: Sections of formalin-fixed paraffin-embedded tissue from the initial biopsies of 275 patients with BM, who had no high-grade dysplasia (HGD) or oesophageal adenocarcinoma (EAC), were stained for p53 by immunohistochemistry. The mean follow-up was 41 months. p53-positive biopsies were divided into four groups: scattered positive cells, multifocal scattered positive cells, aggregates of positive cells, and multifocal aggregates of positive cells. Kaplan-Meier analysis with the log-rank test was used to determine the rate of progression to HGD/EAC. Of the 275 patients, 227 had initial biopsies that were completely negative for p53, and, of these, one (0.4%) progressed to HGD/EAC; none of 24 (0%) patients with scattered positive cells and none of four (0%) of patients with multifocal scattered positive cells progressed. In contrast, five of 16 (31.25%) patients with aggregates of positive cells and three of four (75%) of those with multifocal aggregates of positive cells progressed to HGD/EAC. Kaplan-Meier analysis with log-rank statistics showed the difference in progression rate between the five groups to be highly significant (P < 0.0001). CONCLUSIONS: We conclude that p53 protein accumulation, detected by immunohistochemistry in aggregates of cells, is a significant predictor of malignant progression in patients with BM.
Authors: M Younes; J Lechago; S Chakraborty; M Ostrowski; M Bridges; F Meriano; D Solcher; A Barroso; D Whitman; J Schwartz; C Johnson; A C Schmulen; R Verm; A Balsaver; N Carlson; A Ertant Journal: Scand J Gastroenterol Date: 2000-02 Impact factor: 2.423
Authors: F Kastelein; S van Olphen; E W Steyerberg; M Sikkema; M C W Spaander; C W N Looman; E J Kuipers; P D Siersema; M J Bruno; E W de Bekker-Grob Journal: Gut Date: 2014-07-18 Impact factor: 23.059
Authors: Marek Skacel; Robert E Petras; Lisa A Rybicki; Terry L Gramlich; Joel E Richter; Gary W Falk; John R Goldblum Journal: Am J Gastroenterol Date: 2002-10 Impact factor: 10.864
Authors: R Kim; M R Clarke; M F Melhem; M A Young; M M Vanbibber; A V Safatle-Ribeiro; U Ribeiro; J C Reynolds Journal: Dig Dis Sci Date: 1997-12 Impact factor: 3.199
Authors: E Montgomery; M P Bronner; J R Goldblum; J K Greenson; M M Haber; J Hart; L W Lamps; G Y Lauwers; A J Lazenby; D N Lewin; M E Robert; A Y Toledano; Y Shyr; K Washington Journal: Hum Pathol Date: 2001-04 Impact factor: 3.466
Authors: W Polkowski; J J van Lanschot; F J Ten Kate; J P Baak; G N Tytgat; H Obertop; W J Voorn; G J Offerhaus Journal: Surg Oncol Date: 1995-06 Impact factor: 3.279
Authors: Matthew D Stachler; Nicholas D Camarda; Christopher Deitrick; Anthony Kim; Agoston T Agoston; Robert D Odze; Jason L Hornick; Anwesha Nag; Aaron R Thorner; Matthew Ducar; Amy Noffsinger; Richard H Lash; Mark Redston; Scott L Carter; Jon M Davison; Adam J Bass Journal: Gastroenterology Date: 2018-03-31 Impact factor: 22.682
Authors: Fiebo J C Ten Kate; Lucia Suzuki; Lambert C J Dorssers; Winand N M Dinjens; David T W Jones; Daan Nieboer; Michael Doukas; J Jan B Van Lanschot; Bas P L Wijnhoven; Leendert H J Looijenga; Katharina Biermann Journal: Oncotarget Date: 2017-10-24
Authors: Mark Redston; Amy Noffsinger; Anthony Kim; Fahire G Akarca; Marianne Rara; Diane Stapleton; Laurel Nowden; Richard Lash; Adam J Bass; Matthew D Stachler Journal: Gastroenterology Date: 2021-10-29 Impact factor: 33.883
Authors: Yun Zhang; Katherine M Weh; Connor L Howard; Jean-Jack Riethoven; Jennifer L Clarke; Kiran H Lagisetty; Jules Lin; Rishindra M Reddy; Andrew C Chang; David G Beer; Laura A Kresty Journal: Mol Ther Nucleic Acids Date: 2022-08-17 Impact factor: 10.183
Authors: Ksenia S Maslyonkina; Alexandra K Konyukova; Darya Y Alexeeva; Mikhail Y Sinelnikov; Liudmila M Mikhaleva Journal: Cancer Med Date: 2021-12-06 Impact factor: 4.452